Dr. Anthony D’Ambrosio was recently quoted on the front page of The Record in a story, Potential cancer treatment lies within tumor itself.
The article came out in the July 16, 2012 issue of the Northern New Jersey newspaper and features the clinical trial he and his colleagues are conducting at Valley Hospital on the treatment of glioblastoma multiforme (GBM), a deadly form of brain cancer.
The Phase II trial, headed by principal investigator and researcher Anthony D’Ambrosio, M.D., Director of Valley’s Neuro-Oncology Disease Management Team, is designed to evaluate safety, survival, and immune response in patients treated with a vaccine (HSPPC-96) derived from each patient’s specific tumor cells.
Earlier this summer, Dr. D’Ambrosio administered the vaccine to the first two GBM patients involved in the trial at Valley Hospital. Valley is one of nine sites nationally involved in this novel immunotherapy trial and the only hospital in New Jersey with access to this vaccine.
In The Record, Dr. D’Ambrosio says, “Preliminary data show a significant improvement — patients are living months longer.”
—————-
Read the original article on-line at NorthJersey.com.
For more detailed information on this trial, please contact The Valley Hospital Department of Oncology Clinical Trials at 201-634-5792 or go to www.clinicaltrials.gov.
